Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to $2.2 million.

  • Perspective Therapeutics' Share-based Compensation rose 1045.08% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 12265.64%. This contributed to the annual value of $5.4 million for FY2024, which is 4411.45% up from last year.
  • According to the latest figures from Q3 2025, Perspective Therapeutics' Share-based Compensation is $2.2 million, which was up 1045.08% from $2.4 million recorded in Q2 2025.
  • Perspective Therapeutics' 5-year Share-based Compensation high stood at $2.4 million for Q2 2025, and its period low was $94000.0 during Q1 2021.
  • Over the past 5 years, Perspective Therapeutics' median Share-based Compensation value was $664000.0 (recorded in 2022), while the average stood at $988111.1.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 77133.76% in 2023, then crashed by 5204.68% in 2024.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Share-based Compensation stood at $180000.0 in 2021, then surged by 273.33% to $672000.0 in 2022, then grew by 7.14% to $720000.0 in 2023, then skyrocketed by 186.11% to $2.1 million in 2024, then grew by 4.66% to $2.2 million in 2025.
  • Its Share-based Compensation stands at $2.2 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.1 million for Q1 2025.